XT-150 for Arthrosis
Safety and Efficacy of XT-150 for Facet Joint Osteoarthritis Pain
See full descriptionAbout the trial for Arthrosis
Treatment Groups
This trial involves 3 different treatments. XT-150 is the primary treatment being studied. Participants will be divided into 2 treatment groups. Some patients will receive a placebo treatment. The treatments being tested are in Phase 2 and have already been tested with other people.
About The Treatment
Eligibility
This trial is for patients born any sex aged 18 and older. There are 10 eligibility criteria to participate in this trial as listed below.
Approximate Timelines
Measurement Requirements
This trial is evaluating whether XT-150 will improve 1 primary outcome, 1 secondary outcome, and 3 other outcomes in patients with Arthrosis. Measurement will happen over the course of Day 0 to day 180.
Patient Q & A Section
What is inflammation?
Inflammation is the term that is most commonly used to denote the reaction of the body to foreign or harmful constituents. Inflammation results in localized and systemic responses in the body, which can range from superficial or local symptoms such as pain or swelling, to extreme responses such as fever, and a generalized response can lead to organ dysfunction and death.\n
Can inflammation be cured?
In this pilot study of patients with rheumatoid arthritis, no significant improvement was seen after 24 weeks of therapy with an oral anti-tumour necrosis factor-alpha agent compared with placebo. However, a trend towards improvement was observed in a significant proportion of anti-tumour necrosis factor-alpha-positive patients. Since RA is a chronic inflammatory disease that has an uncertain response to anti-tumour necrosis factor-alpha agents, further studies with a longer followup of these patients are required to determine whether long term remission or clinical improvement is actually achievable.
How many people get inflammation a year in the United States?
Nearly 10% of the U.S. population report having had an inflammatory symptom/condition in the preceding 12 months. The proportion who report having had such an event is considerably higher for individuals with more severe, and often more disabling disorders.
What are the latest developments in xt-150 for therapeutic use?
xt-150 for therapeutic use is still in its early clinical phase; however, recent advances in antibody engineering have provided many promising new options for the development of specific antibody-drug conjugates targeting tumor tissue of diverse targets.
What are the signs of inflammation?
Many conditions in inflammatory bowel disease are hard to diagnose and consequently there is no evidence to support the use of this term. The absence of conclusive evidence does not exclude the possibility that there might be systemic signs of inflammation associated with IBD.
What causes inflammation?
The inflammatory response plays an important role in the body, and there has been mounting evidence that it is one of the causes of many of the chronic diseases of our society. The inflammatory process is tightly regulated to ensure the body's ability to recover from acute infection without tissue injury. Dysregulation can lead to more rapid pathology but is necessary for the proper response to acute infection. Understanding this process gives us the opportunity to block the inflammatory response and prevent disease.
What are common treatments for inflammation?
Treatments for many inflammatory disorders share a common molecular pathway: activation of NF-kappaB transcription factor. Treatments are diverse but many are aimed at blocking the innate response or inhibiting NF-κB activation, although these are not universally effective or safe. Common treatments for arthritis, ankylosing spondylitis, allergies, multiple sclerosis, interstitial cystitis, and psoriasis share numerous similarities in their mechanisms and treatment.
Have there been other clinical trials involving xt-150?
The data suggest that XL110 is associated with very low rates of adverse events in patients with moderate to severe UC. In this small cohort, no significant differences were seen in the incidence of any adverse events between XL110-treated patients and those receiving placebo.
What is the primary cause of inflammation?
The inflammatory response is generally due to an aberrant immune response to a nonpathogenic stimulus such as bacterial, fungal, or viral infection in the intestine. Bacteria, viruses, and parasitic or protozoan infections have been hypothesized as the initiating factor and the innate defense against these pathogens is responsible for an elevated I/M and the development of inflammation.
Does xt-150 improve quality of life for those with inflammation?
The data suggest that it is worthwhile to investigate xt-150 as an intervention for persons with chronic inflammatory diseases (both rheumatoid arthritis and scleroderma). In particular, patients with comorbidity should be included in the trial to minimise placebo responses.
Have there been any new discoveries for treating inflammation?
Although we continue to search for the ideal therapies in the world's worst epidemic for common diseases, it is time we looked at approaches that can treat both the cause and the disease itself. The use of anti-inflammatory drugs as well as the control of the inflammatory response are essential elements to halting and even reversing diseases like rheumatoid arthritis. Drugs such as celecoxib, a nonsteroidal anti-inflammatory drug (NSAID) that reduces the production of inflammatory mediators, may provide valuable insights into novel anti-inflammatory strategies.
How serious can inflammation be?
The high rate of depression, insomnia, fatigue, memory change, and fatigue were all found in this study. It was also found that this is correlated with the severity and severity of these symptoms. The correlation between the severity of depression and fatigue is seen over a short time frame. So the symptoms of the disease seem to be worsening, but at a relatively slow rate.